PDCD1 and melanoma: While ICIs such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 have shown remarkable success in prolonging survival in cancers like melanoma and lung cancer, they simultaneously disrupt immune homeostasis, leading to unintended immune activation against healthy tissues.